185243-69-0

  • Product Name:Etanercept
  • Molecular Formula:H4NO3V
  • Purity:99%
  • Molecular Weight:116.97816
Inquiry

Product Details:

CasNo: 185243-69-0

Molecular Formula: H4NO3V

Quality Manufacturer Supply Best Quality Etanercept 185243-69-0 Safe Transportation

  • Molecular Formula:H4NO3V
  • Molecular Weight:116.97816
  • Vapor Pressure:1.09E-05mmHg at 25°C 
  • Boiling Point:381.8°C at 760 mmHg 
  • Flash Point:178.8°C 
  • PSA:0.00000 
  • Density:1.757g/cm3 
  • LogP:0.00000 

Etanercept(Cas 185243-69-0) Usage

Description

Etanercept is a medication used to manage and treat various autoimmune conditions, including plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis.

Uses

While etanercept is not classified as a traditional immunosuppressant, it does affect the immune system. By inhibiting TNF-α, etanercept can lower the ability of the immune system to fight infections. This can increase the risk of serious infections, including tuberculosis (TB), as well as infections caused by viruses, fungi, or bacteria that have spread throughout the body.

InChI:InChI=1/C4H6N4O12/c9-5(10)17-1-3(19-7(13)14)4(20-8(15)16)2-18-6(11)12/h3-4H,1-2H2/t3-,4+

185243-69-0 Relevant articles

Etanercept A Review of its Use in Rheumatoid Arthritis

Blair Jarvis & Diana Faulds

Drugs, Volume 57, pages 945–966, (1999)

A dose-response effect was apparent with etanercept 0.25 to 16 mg/m2 twice weekly in a randomised, double-blind study in 180 patients. The mean number of swollen or tender joints at the end of the 12-week study decreased by >50% in patients treated with etanercept 16 mg/m2 twice weekly and by >25% in patients treated with placebo.

Effects of Etanercept in Patients With the Metabolic Syndrome

L. Elizabeth Bernstein, MD; Jacqueline Berry, BA; Sunnie Kim, BA;

Arch Intern Med. 2006;166(8):902-908.

Fifty-six subjects with the metabolic syndrome were randomized to administration of either etanercept or identical placebo, 50 mg subcutaneously once a week for 4 weeks. The C-reactive protein level was the primary end point. Effects on other inflammatory markers (including fibrinogen, interleukin 6, and adiponectin), insulin sensitivity, lipid levels, and body composition were also determined.

Relevant Products